https://www.alphaview.kr 실시간 미국 주식 뉴스를 AI로 분석하여 시장 정보를 제공합니다. ko Sun, 25 Oct 2026 19:08:17 GMT https://www.alphaview.kr/images/brand/logo.png https://www.alphaview.kr Copyright 2026 AlphaView. All rights reserved. contact@alphaview.kr (AlphaView) contact@alphaview.kr (AlphaView) 30 https://www.alphaview.kr/news/35831-pharvaris-2026년-1분기-재무-결과-발표-및-사업-업데이트-제공 Tue, 12 May 2026 20:05:00 GMT https://www.alphaview.kr/news/35831-pharvaris-2026년-1분기-재무-결과-발표-및-사업-업데이트-제공 바이오/헬스케어 globenewswire GlobeNewswire https://www.alphaview.kr/news/36062-pharvaris-보통주-1억-3230만-달러-규모의-인수-후-증권-발행-완료-및-인수단의-추가-주식-매수-옵션-전량-행사-발표 Mon, 11 May 2026 20:15:00 GMT https://www.alphaview.kr/news/36062-pharvaris-보통주-1억-3230만-달러-규모의-인수-후-증권-발행-완료-및-인수단의-추가-주식-매수-옵션-전량-행사-발표 금융/자금조달 globenewswire GlobeNewswire https://www.alphaview.kr/news/36329-pharvaris-보통주-1억-1500만-달러-규모-공모-가격-확정 Fri, 08 May 2026 10:00:00 GMT https://www.alphaview.kr/news/36329-pharvaris-보통주-1억-1500만-달러-규모-공모-가격-확정 금융/자금조달 globenewswire GlobeNewswire https://www.alphaview.kr/news/29009-pharvaris-ciic-spring-2026-컨퍼런스에서-데우크리티반트-ir과-xr-병용-요법의-안전성-마진에-대한-증거-발표 Mon, 20 Apr 2026 10:51:50 GMT https://www.alphaview.kr/news/29009-pharvaris-ciic-spring-2026-컨퍼런스에서-데우크리티반트-ir과-xr-병용-요법의-안전성-마진에-대한-증거-발표 바이오/헬스케어 globenewswire GlobeNewswire https://www.alphaview.kr/news/23014-pharvaris-2025년-4분기-및-연간-재무-결과-보고-및-사업-업데이트-제공 Thu, 02 Apr 2026 10:52:22 GMT https://www.alphaview.kr/news/23014-pharvaris-2025년-4분기-및-연간-재무-결과-보고-및-사업-업데이트-제공 바이오/헬스케어 globenewswire GlobeNewswire https://www.alphaview.kr/news/20606-유전성-혈관부종-발작-예방-및-필요시-치료에-대한-deucrictibant의-효능-및-안전성-증거가-the-lancet-haematology에 Fri, 20 Mar 2026 10:51:49 GMT https://www.alphaview.kr/news/20606-유전성-혈관부종-발작-예방-및-필요시-치료에-대한-deucrictibant의-효능-및-안전성-증거가-the-lancet-haematology에 바이오/헬스케어 globenewswire GlobeNewswire https://www.alphaview.kr/news/72291-pharvaris-2026년-전략적-우선순위-발표 Mon, 12 Jan 2026 11:50:57 GMT https://www.alphaview.kr/news/72291-pharvaris-2026년-전략적-우선순위-발표 바이오/헬스케어 globenewswire GlobeNewswire